Artykuły udostępnione publicznie: - G. IzquierdoWięcej informacji
Niedostępne w żadnym miejscu: 10
Predictors and dynamics of postpartum relapses in women with multiple sclerosis
SE Hughes, T Spelman, OM Gray, C Boz, M Trojano, A Lugaresi, ...
Multiple Sclerosis Journal 20 (6), 739-746, 2014
Upoważnienia: UK Medical Research Council
Lipid‐specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with …
LM Villar, L Costa‐Frossard, T Masterman, O Fernandez, X Montalban, ...
Annals of neurology 77 (3), 447-457, 2015
Upoważnienia: Government of Spain
Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice
V Abraira, JC Alvarez-Cermeno, R Arroyo, C Cámara, B Casanova, ...
Journal of immunological methods 371 (1-2), 170-173, 2011
Upoważnienia: Government of Spain
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis
M Comabella, AB Caminero, S Malhotra, L Agulló, O Fernández, ...
Neurology 80 (22), 2010-2016, 2013
Upoważnienia: Government of Spain
Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice
M Espiño, V Abraira, R Arroyo, L Bau, C Cámara, L Campos-Ruiz, ...
Clinica Chimica Acta 438, 67-69, 2015
Upoważnienia: Government of Spain
The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli
M Karaky, A Alcina, M Fedetz, C Barrionuevo, V Potenciano, C Delgado, ...
Multiple Sclerosis Journal 22 (8), 999-1006, 2016
Upoważnienia: Government of Spain
Study of the anti‐JCV antibody levels in a Spanish multiple sclerosis cohort
MI Dominguez‐Mozo, M Rus, JL Santiago, G Izquierdo, I Casanova, ...
European Journal of Clinical Investigation 47 (2), 158-166, 2017
Upoważnienia: Government of Spain
Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis: a subgroup analysis from three international cohorts
S Sharmin, M Lefort, JB Andersen, E Leray, D Horakova, EK Havrdova, ...
CNS drugs 35, 1217-1232, 2021
Upoważnienia: National Health and Medical Research Council, Australia, Agence Nationale de …
Risk of secondary progressive multiple sclerosis after early worsening of disability
W Dzau, S Sharmin, F Patti, G Izquierdo, S Eichau, A Prat, M Girard, ...
Journal of Neurology, Neurosurgery & Psychiatry 94 (12), 984-991, 2023
Upoważnienia: National Health and Medical Research Council, Australia
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry
A Signori, M Ponzano, T Kalincik, S Ozakbas, D Horakova, EK Havrdova, ...
Journal of Neurology, Neurosurgery & Psychiatry 95 (7), 620-625, 2024
Upoważnienia: Swiss National Science Foundation, National Health and Medical Research …
Dostępne w jakimś miejscu: 123
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor
V Rothhammer, ID Mascanfroni, L Bunse, MC Takenaka, JE Kenison, ...
Nature medicine 22 (6), 586-597, 2016
Upoważnienia: US National Institutes of Health, German Research Foundation
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
Upoważnienia: National Health and Medical Research Council, Australia, UK Medical Research …
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
Upoważnienia: National Health and Medical Research Council, Australia
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ...
The Lancet Neurology 19 (4), 307-316, 2020
Upoważnienia: National Health and Medical Research Council, Australia, National Institute …
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis
FJ Quintana, MF Farez, V Viglietta, AH Iglesias, Y Merbl, G Izquierdo, ...
Proceedings of the National Academy of Sciences 105 (48), 18889-18894, 2008
Upoważnienia: US National Institutes of Health
Geographical variations in sex ratio trends over time in multiple sclerosis
M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ...
PloS one 7 (10), e48078, 2012
Upoważnienia: Canadian Institutes of Health Research
Toll-like receptor 2 and poly (ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE
MF Farez, FJ Quintana, R Gandhi, G Izquierdo, M Lucas, HL Weiner
Nature immunology 10 (9), 958-964, 2009
Upoważnienia: US National Institutes of Health
Defining reliable disability outcomes in multiple sclerosis
T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ...
Brain 138 (11), 3287-3298, 2015
Upoważnienia: National Health and Medical Research Council, Australia
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ...
Annals of neurology 80 (1), 89-100, 2016
Upoważnienia: National Health and Medical Research Council, Australia
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ...
Brain 136 (12), 3609-3617, 2013
Upoważnienia: National Health and Medical Research Council, Australia
Informacje na temat publikacji i finansowania automatycznie określa program komputerowy